J Hematol Oncol: University participants have discovered important regulatory roles in acute myeloid leukemia with new small molecule RNA.

Recently, !---- professor Zeng Hui, director of the Department of Hematology, a clinical first-level leader at the First Hospital affiliated with Jinan University, has made important progress in the field of leukemia resistance, publishing the research results of "Roles of Theos of Hsa-miR-12462 and SLC9A1 in myeloid" onlineProfessor Zeng Hui is the only communication author of this paper, the main author of the exhibition is the chief physician, and the first hospital affiliated with Jinan University is the only communication unitAcute myeloid leukemia (AML) is a high incidence of malignant tumors in the blood system, in addition to the acute early granulocytic leukemia prognosis is better, other types of AML survival is short, high mortality rate, a serious threat to people's health and lifeAt present, chemotherapy with alyginioside is the core treatment plan of AML, although hematopoietic stem cell transplantation can effectively cure AML, but due to the increase of bone marrow inhibition infection after chemotherapy and the emergence of complications after hematopoietic stem cell transplantation, the prognosis of most patients is still not optimisticAcute myeloid leukemia treatment cycle is long, treatment drugs are expensive, and toxic side effects are large, which brings great pain and financial burden to patients, families and society, so screening new targeted treatment drugs for AML patients is extremely importantMicroRNA (miRNA) is a small, non-coding RNA that plays an important role in post-transcription gene regulation by inhibiting target messenger RNA (mRNAs)There is a widerange imbalance of miRNA in acute myeloid leukemia, which acts as a cancer gene or tumor suppressor that can affect the leukemia process, including proliferation, differentiation, self-renewal, epigenetic regulation, invivial disease progression, and chemotherapy resistanceThis study resulted in miRNA sequencing analysis of a large number of bone marrow samples in clinical AML patients, screened an unreported miRNA (named miR-12462), which was associated with the prognosis of AML patients through clinical analysis, and for the first time in cell and animal models, it was shown to have an important role in inhibiting proliferation, promoting apoptosis, enhancing chemotherapy sensitivity, and reducing tumor loadSLC9A1 is the most common isomer in the family of Na/H-plus exchangers prevalent in all mammalian cells, and has the effect of promoting tumor cell movement, invasion, proliferation, growth and the avoidance of chemically therapeutic cell deathThe study found that SLC9A1 was the target gene of miR-12462, and that miR-12462 played a role in AML by inhibiting the downstream target gene SLC9A1This study is the first to reveal that miR-12462 provides new ideas for the treatment of patients with refractive/relapsed AML by targeting the specific mechanism of SLC9A1 in AML resistanceThis project has been the guidance and help of Professor Li Yangqiu, as well as the National Natural Science Foundation of China and Jinan University affiliated with the first hospital to introduce talent start-up fund support, and has applied for a national invention patentZeng Hui, director, professor and doctoral tutor of the first hospital affiliated with Jinan University, has long been engaged in clinical front-line work, specializing in the diagnosis and treatment of malignant tumors in the hematologic system and hematopoietic stem cell transplantation, especially for acute myeloid leukemia, which is difficult to treat recurrence, has a more in-depth studyHe is also a member of the China Society of Pathological Physiology Experimental Blood Credit Stakes, a member of the China Anti-Cancer Association Blood Tumor Credit Committee, a secretary of the Blood Physiology Branch of the Chinese Physiological Society, a member of the Blood Credit Committee of the Guangdong Provincial Medical Association, a member of the Professional Committee of the Guangdong Anti-Cancer Association, a member of the Standing Committee of the Hematology Branch of the Guangdong Society of Precision Medicine Applications, etc., and has published more than 10 research papers in recent years as a first/communication author in internationally renowned journals such as Cell StemExpert review (Professor Chen Guo Jinan University) is well known that tumor cells use glucose as a carbon source, even in the case of oxygen, also rely on the glycoenzyme pathway to provide material and energy, which is known as the Warburg effectAerobic sugar enzyme metabolism supports the rapid proliferation of cells, but also produces a large number of acids in the form of hydrogen ionsIn order to cope with the production of acids, tumor cells use ion transport systems to pump excess hydrogen ions from glycoenzymes out of the cells, thus maintaining the tumor's alkaline intracellular pH environment Among them, the NHE1 protein encoded by the SLC9A1 gene is the main machine for removing excess hydrogen ions in the cell Moreover, SLC9A1 has been shown to play an important role in the development of tumors including pancreatic and lung cancer However, little is known about the endogenous regulatory mechanism of SLC9A1 The research work of Professor Zeng Hui's team found that hsa-miR-12462 is an important regulatory molecule of SLC9A1, and hsa-miR-12462 can directly inhibit SLC9A1 protein expression Hsa-miR-12462 is a new acute myeloid leukemia inhibitor, and patient specimens, cells and biochemical experiments have been confirmed This study provides new scientific evidence for understanding the development mechanism of acute myeloid leukemia and, more importantly, new strategies and methods for reversing the pH microenvironment in tumor cells